This paper is only available as a PDF. To read, Please Download here.
Abstract
The Norplant® subdermal implants system is rapidly becoming acceptable as a contraceptive system
all over the world. Earlier studies in Singapore indicated that the implants do not
appear directly contributory to cardiovascular risk. However, extraneous environmental
effects could have contributed to the observed changes.
In this study, when nonsteroid copper intrauterine device (IUD) users were used as
control, we have shown that the findings are in concordance with the results of the
earlier studies. There was a decrease in serum triglycerides, total cholesterol, and
HDL and LDL cholesterol over the period of study. However, despite these changes,
the HDL cholesterol/total cholesterol ratio remained stable and was above 0.200. As
regards apolipoprotein, there was generally a significant fall in apolipoprotein AI,
AII, and B. As a result, the apolipoprotein ![Math Eq]()
ratio showed a significant decrease in the first 3 months before increasing close
to its preinsertion value at 2 years. Similarly, the apolipoprotein ![Math Eq]()
ratio also stabilized at the end of 2 years.
ratio showed a significant decrease in the first 3 months before increasing close
to its preinsertion value at 2 years. Similarly, the apolipoprotein 
ratio also stabilized at the end of 2 years.This study thus confirms our earlier findings that Norplant implants do not appear
directly contributory to cardiovascular risk.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A three-year evaluation of metabolic changes in Singaporean Norplant acceptors.Adv Contracept. 1990; 6: 11-21
- Effect of Norplant implants on liver, lipid and carbohydrate metabolism.Contraception. 1992; 45: 141-153
- High density lipoprotein as a protective factor against coronary heart disease.A J Med. 1977; 62: 707-711
- Cholesterol in the prediction of atherosclerotic disease.Ann Intern Med. 1979; 90: 85-91
- Impact of hormone replacement on serum lipids, lipoproteins, body composition and atherosclerosis: clinical and experimental studies.Dan Med Bull. 1994; 41: 412-422
- Hormone replacement therapy and cardiovascular disease: the rabbit model.Br J Obstet Gynaecol. 1996; 103: 49-52
- Hormone replacement therapy and coronary artery atherosclerosis: the monkey model.Br J Obstet Gynaecol. 1996; 103: 53-58
- Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.N Engl J Med. 1981; 304: 560-563
- L-norgestrel and progesterone have different influences on plasma lipoproteins.Eur J Clin Invest. 1983; 13: 447-453
- Clinical chemistry in women treated with levonorgestrel implants (Norplant®), or TCu-200-IUD.Contraception. 1983; 27: 281-288
- Effect of levonorgestrel contraceptive implants Norplant® on serum lipids.Contraception. 1984; 30: 413-419
- Cholesterol and HDL cholesterol values in women during use of subdermal implant releasing levonorgestrel.Contraception. 1985; 32: 163-171
- HDL-cholesterol and other lipids in coronary heart disease.Circulation. 1977; 55: 767-772
- Lipid metabolism in Norplant-2® users—a two-year follow-up study. Total cholesterol, triglycerides, lipoproteins and apolipoprotein.Contraception. 1992; 45: 21-37
Article info
Publication history
Accepted:
May 13,
1997
Received in revised form:
March 11,
1997
Received:
November 12,
1996
Identification
Copyright
© 1997 Published by Elsevier Inc.
